These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8489711)

  • 21. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families.
    Cavaciuti E; Laugé A; Janin N; Ossian K; Hall J; Stoppa-Lyonnet D; Andrieu N
    Genes Chromosomes Cancer; 2005 Jan; 42(1):1-9. PubMed ID: 15390180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer risks in BRCA2 mutation carriers.
    Breast Cancer Linkage Consortium
    J Natl Cancer Inst; 1999 Aug; 91(15):1310-6. PubMed ID: 10433620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant TP53 disrupts age-related accumulation patterns of somatic mutations in multiple cancer types.
    Zhang W; Flemington EK; Zhang K
    Cancer Genet; 2016 Sep; 209(9):376-380. PubMed ID: 27751354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic cell mutations in cancer epidemiology.
    Albertini RJ; Hayes RB
    IARC Sci Publ; 1997; (142):159-84. PubMed ID: 9354918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer Incidence in BRCA1 mutation carriers.
    Thompson D; Easton DF;
    J Natl Cancer Inst; 2002 Sep; 94(18):1358-65. PubMed ID: 12237281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer.
    Fox EJ; Salk JJ; Loeb LA
    Genome Med; 2016 Mar; 8(1):30. PubMed ID: 26987311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries.
    Olsen JH; Hahnemann JM; Børresen-Dale AL; Brøndum-Nielsen K; Hammarström L; Kleinerman R; Kääriäinen H; Lönnqvist T; Sankila R; Seersholm N; Tretli S; Yuen J; Boice JD; Tucker M
    J Natl Cancer Inst; 2001 Jan; 93(2):121-7. PubMed ID: 11208881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct mutation accumulation rates among tissues determine the variation in cancer risk.
    Hao D; Wang L; Di LJ
    Sci Rep; 2016 Jan; 6():19458. PubMed ID: 26785814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer risks and mortality in heterozygous ATM mutation carriers.
    Thompson D; Duedal S; Kirner J; McGuffog L; Last J; Reiman A; Byrd P; Taylor M; Easton DF
    J Natl Cancer Inst; 2005 Jun; 97(11):813-22. PubMed ID: 15928302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenomic Consequences of Coding and Noncoding Driver Mutations.
    Yao X; Xing M; Ooi WF; Tan P; Teh BT
    Trends Cancer; 2016 Oct; 2(10):585-605. PubMed ID: 28741489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention.
    Tomasetti C; Li L; Vogelstein B
    Science; 2017 Mar; 355(6331):1330-1334. PubMed ID: 28336671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutational model of carcinogenesis.
    Morris JA
    Anticancer Res; 1991; 11(5):1731-4. PubMed ID: 1768044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method for estimating cancer risk in p53 mutation carriers.
    Le Bihan C; Bonaiti-Pellie C
    Cancer Detect Prev; 1994; 18(3):171-8. PubMed ID: 8076379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides.
    Soussi T; Béroud C
    Hum Mutat; 2003 Mar; 21(3):192-200. PubMed ID: 12619105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical correlates of TP53 somatic mutations in cancer.
    Murnyák B; Hortobágyi T
    Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell death in genome evolution.
    Teng X; Hardwick JM
    Semin Cell Dev Biol; 2015 Mar; 39():3-11. PubMed ID: 25725369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the unreliability of the axiom of randomness: the case of random mutations in biology.
    Matioli GT
    Med Hypotheses; 1997 Aug; 49(2):181-2. PubMed ID: 9278933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions.
    Tomasetti C; Vogelstein B
    Science; 2015 Jan; 347(6217):78-81. PubMed ID: 25554788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
    Brose MS; Rebbeck TR; Calzone KA; Stopfer JE; Nathanson KL; Weber BL
    J Natl Cancer Inst; 2002 Sep; 94(18):1365-72. PubMed ID: 12237282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.